Invivyd (NASDAQ:IVVD) Insider Sells $30,281.02 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Timothy Edward Lee sold 19,663 shares of Invivyd stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $1.54, for a total value of $30,281.02. Following the sale, the insider owned 138,681 shares in the company, valued at $213,568.74. This represents a 12.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Timothy Edward Lee also recently made the following trade(s):

• On Wednesday, February 18th, Timothy Edward Lee sold 20,964 shares of Invivyd stock. The stock was sold at an average price of $1.58, for a total transaction of $33,123.12.

Invivyd Price Performance

Shares of NASDAQ:IVVD traded up $0.10 during midday trading on Wednesday, reaching $1.65. The company had a trading volume of 1,468,415 shares, compared to its average volume of 3,015,442. The stock’s fifty day moving average price is $2.19 and its 200-day moving average price is $1.75. The stock has a market capitalization of $384.65 million, a P/E ratio of -3.51 and a beta of 0.60. Invivyd, Inc. has a one year low of $0.46 and a one year high of $3.07.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in IVVD. Catalyst Funds Management Pty Ltd acquired a new position in shares of Invivyd during the second quarter valued at $27,000. Vanguard Personalized Indexing Management LLC lifted its position in Invivyd by 238.6% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company’s stock valued at $29,000 after purchasing an additional 28,146 shares during the last quarter. Miller Financial Services LLC lifted its position in Invivyd by 37.8% in the 4th quarter. Miller Financial Services LLC now owns 51,000 shares of the company’s stock valued at $126,000 after purchasing an additional 14,000 shares during the last quarter. ProShare Advisors LLC acquired a new position in Invivyd during the 4th quarter valued at about $30,000. Finally, UBS Group AG grew its position in Invivyd by 683.8% in the 4th quarter. UBS Group AG now owns 1,050,923 shares of the company’s stock worth $2,596,000 after purchasing an additional 916,842 shares during the last quarter. 70.36% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on IVVD. HC Wainwright increased their price target on shares of Invivyd from $5.00 to $10.00 and gave the stock a “buy” rating in a research report on Friday, October 31st. Weiss Ratings reiterated a “sell (e+)” rating on shares of Invivyd in a research report on Monday, December 29th. BTIG Research reissued a “buy” rating on shares of Invivyd in a research report on Wednesday, January 21st. Zacks Research upgraded Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Finally, D. Boral Capital reiterated a “hold” rating on shares of Invivyd in a research note on Tuesday, November 25th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $8.00.

Trending Headlines about Invivyd

Here are the key news stories impacting Invivyd this week:

• Neutral Sentiment: Multiple Form 4 filings disclose open‑market sales (no new corporate/clinical announcements). The disclosures are routine SEC insider-sale filings rather than earnings or clinical-data releases. Representative SEC Filing
• Neutral Sentiment: Aggregate size and liquidity context — filings show insiders sold a total of over ~220,000 shares across Feb. 17–18 (multiple executives, see items below). Today’s volume (≈1.47M) is below the stock’s 3M average, which can amplify price moves on relatively modest buying or selling flows.
• Negative Sentiment: Jill Andersen — sold 32,771 shares on 2/17 at ~$1.54 and 34,939 shares on 2/18 at ~$1.58; filings show a double‑digit percentage reduction in her holdings. SEC Filing – Jill Andersen
• Negative Sentiment: Timothy Edward Lee — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale reduced his ownership by ~12–15%. SEC Filing – Timothy Lee
• Negative Sentiment: William E. Duke (CFO) — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; filings show ~13–16% reductions in his holdings. SEC Filing – William Duke
• Negative Sentiment: Julie Green — sold 19,663 shares on 2/17 at ~$1.54 and 20,964 on 2/18 at ~$1.58; each sale trimmed her stake by ~13–16%. SEC Filing – Julie Green
• Negative Sentiment: Robert D. Allen III — sold 18,189 shares on 2/17 at ~$1.54 and 19,392 on 2/18 at ~$1.58; filings show ~12–14% reductions in his holdings. SEC Filing – Robert Allen

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.